Page last updated: 2024-08-23

phosphotyrosine and pd 166326

phosphotyrosine has been researched along with pd 166326 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bornmann, WG; Clarkson, B; Ilaria, RL; Tong, WP; Veach, DR; Wolff, NC	1

Other Studies

1 other study(ies) available for phosphotyrosine and pd 166326

Article	Year
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood, 2005, May-15, Volume: 105, Issue:10 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Mutation; Phosphorylation; Phosphotyrosine; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Signal Transduction; Stem Cell Factor; Survival Rate; Time Factors	2005

Article

Year

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Blood, 2005, May-15, Volume: 105, Issue:10

Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Mutation; Phosphorylation; Phosphotyrosine; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Signal Transduction; Stem Cell Factor; Survival Rate; Time Factors

2005